The studies will examine whether
substantive risk information in direct-to-consumer
character-space-limited prescription drug communications is
effective in communicating risks when benefit claims are made, or
whether a link to the risk information is sufficient. We plan to
conduct two pretests and four main studies, each 20 minutes long,
with 277 participants in each pretest (total = 554) and 469
participants in each main study (total = 1,876). We will manipulate
whether (1) the communication includes substantive risk
information, (2) whether the landing page includes benefit
information, and (3) whether participants are instructed to browse
or search for information. After viewing the study materials,
participants will complete a questionnaire that assesses their
retention of the risk information and their perceptions of the
drug’s risks and benefits.
Ila Mizrachi 301 796-7726
ila.mizrachi@fda.hhs.gov
No
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.